Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.

摘要: Cryptosporidiosis causes life-threatening diarrhea in infants, but the best available treatment is only modestly efficacious. Rodents infected with relevant Cryptosporidium species do not develop diarrhea, which complicates drug development. parvum infection of dairy calves, however, an illness like that seen infants. Here, clinical and microbiologic anti-Cryptosporidium efficacy piperazine-based compound MMV665917 was demonstrated neonatal calves. Oral administration (22 mg/kg once daily) begun two days after onset severe continued for seven days. Treatment resulted prompt resolution reduced total fecal oocyst shedding by ~94%. useful treatment, rather than just prophylaxis, since it safe effective when administered well diarrhea. Furthermore, even though all animals received intensive supportive care, there a strong trend towards improved secondary health outcomes, including general health, appetite, dehydration measures amongst treated animals. These data establish as outstanding lead